Can flecainide affect blood pressure?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 19, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Flecainide can affect blood pressure, although it is not its primary effect, and patients should be monitored for potential hypotension, especially those with pre-existing low blood pressure or heart failure. Flecainide is an antiarrhythmic medication primarily used to treat abnormal heart rhythms like atrial fibrillation and supraventricular tachycardia. According to the 2016 ESC guidelines for the management of atrial fibrillation 1, flecainide can cause hypotension, atrial flutter with 1:1 conduction, and QT prolongation, and should be avoided in patients with ischemic heart disease and/or significant structural heart disease.

Key Considerations

  • Flecainide works by blocking sodium channels in heart cells, which can reduce the force of heart contractions and affect blood pressure.
  • The typical adult dose of flecainide ranges from 50-200 mg taken twice daily, with dosing adjusted based on response and side effects.
  • Patients taking flecainide should be monitored regularly for both heart rhythm and blood pressure changes.
  • If significant dizziness, lightheadedness, or fainting occurs while taking flecainide, patients should contact their healthcare provider immediately.

Important Warnings

  • Flecainide can cause severe hypotension in some patients, especially those with pre-existing low blood pressure or heart failure.
  • Patients with ischemic heart disease and/or significant structural heart disease should avoid taking flecainide due to the risk of proarrhythmia.
  • Regular monitoring and dose adjustments are crucial to minimize the risk of adverse effects and ensure effective treatment.

From the FDA Drug Label

In less than 1% of patients: Body as a Whole: swollen lips, tongue and mouth; arthralgia, bronchospasm, myalgia; Cardiovascular: angina pectoris, second-degree and third-degree AV block, bradycardia, hypertension, hypotension;

Flecainide may affect blood pressure, as evidenced by reports of hypertension and hypotension in less than 1% of patients 2, 2. However, the exact relationship between flecainide and blood pressure is not clearly established.

  • Key points:
    • Flecainide has been associated with hypertension and hypotension in some patients.
    • The frequency of these effects is less than 1%.
    • The relationship between flecainide and blood pressure is not fully understood.

From the Research

Flecainide and Blood Pressure

  • The provided studies do not directly address the effect of flecainide on blood pressure 3, 4, 5, 6, 7.
  • The studies focus on the use of flecainide for the treatment of atrial fibrillation, supraventricular arrhythmias, and ventricular tachyarrhythmias, with discussions on its efficacy, safety, and potential risks 3, 4, 5, 6.
  • One study mentions the use of flecainide in combination with beta-blockers for the treatment of arrhythmogenic right ventricular cardiomyopathy, but does not discuss its impact on blood pressure 7.
  • There is no direct evidence in the provided studies to suggest that flecainide has a significant effect on blood pressure 3, 4, 5, 6, 7.

Limitations of the Studies

  • The studies primarily focus on the antiarrhythmic effects of flecainide and do not investigate its potential impact on blood pressure 3, 4, 5, 6, 7.
  • The lack of discussion on blood pressure in the studies suggests that it may not be a primary concern or a significant side effect of flecainide treatment 3, 4, 5, 6, 7.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Use of Flecainide for the Treatment of Atrial Fibrillation.

The American journal of cardiology, 2020

Research

Safety and efficacy of flecainide associated with beta-blockers in arrhythmogenic right ventricular cardiomyopathy.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2022

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.